0001140361-19-018070.txt : 20191007
0001140361-19-018070.hdr.sgml : 20191007
20191007191518
ACCESSION NUMBER: 0001140361-19-018070
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191007
FILED AS OF DATE: 20191007
DATE AS OF CHANGE: 20191007
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SCHADE CHRISTIAN S
CENTRAL INDEX KEY: 0001214496
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39069
FILM NUMBER: 191141662
MAIL ADDRESS:
STREET 1: MEDAREX
STREET 2: 707 STATE ROAD
CITY: PRINCETON
STATE: NJ
ZIP: 08540
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aprea Therapeutics, Inc.
CENTRAL INDEX KEY: 0001781983
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 535 BOYLSTON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 6095104718
MAIL ADDRESS:
STREET 1: 535 BOYLSTON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
4
1
form4.xml
FORM 4
X0306
4
2019-10-07
0001781983
Aprea Therapeutics, Inc.
APRE
0001214496
SCHADE CHRISTIAN S
535 BOYLSTON STREET
BOSTON
MA
02116
true
true
President & CEO
Common Stock
2019-10-07
4
P
0
1000
15
A
1000
I
By adult child
Common Stock
2019-10-07
4
P
0
1000
15
A
1000
I
By adult child
Common Stock
2019-10-07
4
P
0
1000
15
A
1000
I
By adult child
Common Stock
2019-10-07
4
P
0
1000
15
A
1000
I
By adult child
Common Stock
2019-10-07
4
P
0
1000
15
A
1000
I
By adult child
Common Stock
2019-10-07
4
P
0
1000
15
A
1000
I
By adult child
Common Stock
2019-10-07
4
P
0
5000
15
A
5000
I
By spouse
Common Stock
160
D
Stock Option (right to Buy)
15
2019-10-07
4
A
0
306085
0
A
2029-10-02
Common Stock
306085
306085
D
The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.
Twenty-five percent of these options vest on October 2, 2020, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions.
/s/ Scott M. Coiante, attorney-in-fact
2019-10-07